Attention is focusing on whether progress will be made in the discussion on insurance benefits for Luxturna, a one-shot retinal disease treatment. As a result of the coverage, Novartis Korea recently submitted additional supplemental data for Inherited Retinal Dystrophy treatment Luxturna requested by the HIRA. The drug submitted an application for reimbursement in September 2021, but there was no progress in the listing process, and it was presented to the Pharmaceutical Reimbursement Evaluation Committee in March but failed to set reimbursement standards.

It is known that during the evaluation process of Luxturna, there was a difference of opinion over the terms of the Risk Sharing Agreement (refund